Motilal Oswal NTDOP PMS Review: Performance, Fees & Should You Stay Invested?

What Works	What Doesn’t
Since-inception CAGR of 13.97% beats benchmark (11.46%) — a genuine 18-year track record that isn’t fabricated	5-year CAGR of 8.88% trails the benchmark’s 12.28% — you paid 2.5% for below-index returns over the period most relevant to you
~93% away from BSE 500 — genuinely differentiated portfolio, not a mutual fund clone	Standard deviation of 16.7% vs benchmark’s 13% — more volatility, not less, for that 5-year underperformance
Mid and small-cap tilt (48.9% + 26.3%) offers real differentiation from standard MF portfolios	Sharpe ratio of 0.5 vs benchmark’s 0.7 — the strategy is delivering less return per unit of risk taken
Buy-and-hold philosophy with 8 stocks held 12+ years shows genuine mandate conviction	2-year CAGR exactly matches benchmark at 4.14% — you carried all the active risk for zero active return

Verdict: The NTDOP has a legitimate since-inception story.

But the data you need to focus on is not from 2007.

It is from the last 5 years — where the strategy delivered 8.88% CAGR while the benchmark delivered 12.28%, and while you paid 2.5% every year for the privilege.

The numbers are asking you a question. This article helps you answer it honestly.

Table of Contents:

1. Who Should Read This
2. Who This PMS May Still Suit
3. Who Should Likely Avoid This PMS
4. What Is the Motilal Oswal NTDOP?
5. Performance Review
6. The Fee Reality
7. The Zero-Based Thinking Test
8. Decision Factor Scorecard
9. The Core Portfolio Architecture Question
10. What a Genuinely Complementary PMS Looks Like
11. Exit Considerations
12. Key Takeaways
13. FAQ
14. Our Approach

Who Should Read This

• You are invested in the Motilal Oswal NTDOP and haven’t sat down with the actual trailing return numbers — not the since-inception chart, but the 3-year and 5-year columns
• You’re paying 2.5% per year and want to know honestly whether that fee has been generating value or quietly compounding against you
• You’ve been told the recent underperformance is a “style headwind” and want an independent view on whether that explanation is supported by the data
• You hold a mutual fund portfolio and want to understand what the NTDOP is genuinely adding — versus what it’s expensively duplicating
• You are an HNI investor who made a considered decision and are now ready to review it with fresh eyes and current data in front of you

Who This PMS May Still Suit

• Investors who entered before 2019 and have a genuine since-inception gain that makes the long-horizon case personally real — not just a marketing slide
• Those with a 7–10 year remaining horizon who find the India GDP growth thesis intellectually compelling and can absorb fee drag in lean alpha years while they wait
• Investors who have verified that their existing mutual fund portfolio holds predominantly large-cap or index funds — and who therefore see the NTDOP’s mid and small-cap concentration as genuinely additive
• Those already past the 1-year exit load window who are close to a natural review point and want to hold through one more market cycle with a clear, written thesis

Who Should Likely Avoid This PMS

• Anyone whose mutual fund portfolio already has significant mid-cap or small-cap exposure — the NTDOP’s genuine differentiation is in that segment, and duplication here is a real risk
• Investors who entered in the last 3 years and are sitting on a 5-year CAGR of 8.88% against a benchmark at 12.28% — the data is asking a pointed question, and the 2.5% fee is making it louder every month
• Those who cannot clearly articulate why they are still invested beyond “the since-inception returns are good” — that is not a thesis; it is a legacy
• Investors who need the risk-adjusted efficiency of their portfolio to improve — a Sharpe ratio of 0.5 vs the benchmark’s 0.7 means you are taking more risk than the market and getting less return for it

What Is the Motilal Oswal NTDOP?

Key Facts

Strategy	Next Trillion Dollar Opportunity Strategy (NTDOP) — PMS
Benchmark	BSE 500 TRI
Inception Date	August 3, 2007
Fund Manager	Mr. Vaibhav Agrawal, CIO — Alternates
AUM	₹4,421 crore
Total Stocks	~31
Market Cap Mix	Large Cap: 20.9% / Mid Cap: 48.9% / Small Cap: 26.3% / Cash: 4%
Minimum Investment	₹50 lakhs
Fixed Fee	2.5% p.a.
Variable Fee	20% profit sharing above 8% hurdle
Exit Load	2% (Year 1), Nil thereafter
Benchmark Deviation	~93% away from BSE 500

The stated mandate is to invest in sectors and companies that can benefit from India’s successive phases of GDP growth — the “next trillion dollar” opportunity.

The approach is buy-and-hold, bottom-up, and genuinely concentrated, with 8 stocks held for over 12 years.

Page Industries has been held since inception. That is not performance theatre. That is real conviction.

And here is where the honest framing matters: this is one of the more genuinely differentiated PMS mandates you will find in India.

At 93% away from the BSE 500 benchmark, it is not recycling the same Reliance-HDFC Bank-Infosys universe that your mutual funds already hold. The mid and small-cap tilt is real.

The concentration is deliberate. The philosophy has internal consistency.

So why is the 5-year CAGR 8.88% while the benchmark delivered 12.28%?

And why is your portfolio taking more volatility than the index — standard deviation of 16.7% vs 13% — while earning less?

That is the question the data is asking. And it deserves a clear-eyed answer.

Performance Review

When did you last look at the full trailing return table — not just the since-inception line that gets highlighted in every pitch deck, but the columns covering the years you’ve actually been invested?

Trailing Returns (as on May 31, 2026)

Period	NTDOP	BSE 500 TRI	Alpha (+/-)
1 Month	0.71%	-0.17%	+0.88%
3 Months	2.03%	-2.34%	+4.37%
6 Months	-3.97%	-5.39%	+1.42%
1 Year	-0.47%	-0.07%	-0.40%
2 Years (CAGR)	4.14%	4.14%	0.00%
3 Years (CAGR)	13.46%	13.45%	+0.01%
5 Years (CAGR)	8.88%	12.28%	-3.40%
Since Inception (CAGR)	13.97%	11.46%	+2.51%

Performance data: Net of all fees and expenses. TWRR basis.

Calendar Year Performance

Year	NTDOP	Notes
CY 2007	13.04%	Inception year
CY 2009	111.15%	Post-crisis recovery — exceptional
CY 2011	21.6%
CY 2013	54.21%
CY 2015	15.59%
CY 2017	13.41%
CY 2019	-5.34%
CY 2021	71.81%	Mid-small cap bull run
CY 2023	42.13%
CY 2024	28.45%
CY 2025	-5.82%
CY 2026 YTD	-7.02%

Here is what the data is telling you — and it requires more than one read.

The short-term picture (1M, 3M, 6M) is actually encouraging. The strategy is outperforming the benchmark in the recent downturn — which is what you want active management to do.

And the since-inception CAGR of 13.97% vs 11.46% for the benchmark represents a genuine 2.51% per annum edge compounded over 18 years.

The ₹1 crore invested at inception is worth significantly more than what a passive strategy would have delivered. That is real.

But wait — look at this more carefully. The 5-year CAGR of 8.88% trails the benchmark by 3.40% per annum, net of fees.

The 2-year CAGR is exactly 4.14% vs 4.14% — you carried all the active risk and concentration for precisely zero incremental return.

And the 1-year alpha is barely negative at -0.40%.

These are not catastrophic numbers, but they are not what you signed up for when you agreed to pay 2.5% annually.

The calendar year table adds important context.

CY 2009 (111%) and CY 2021 (71.81%) are the years that built the since-inception alpha.

The strategy delivers outsized returns in liquidity-driven mid and small-cap rallies — and that is a genuine feature of the mandate, not a fluke. The problem is CY 2019 (-5.34%), CY 2025 (-5.82%), and CY 2026 YTD (-7.02%) — the drawdown years hurt more than the benchmark in recent cycles, which is what a standard deviation of 16.7% vs 13% is quietly telling you in the risk ratio data.

Is this a structural failure or a cycle positioning issue? Honest answer: it is probably both.

The strategy’s heavy allocation to Financial Services (40.1%) and Capital Goods (16.9%) — with zero exposure to defensives like FMCG and Pharma in meaningful weight — means it will lag when risk appetite contracts.

Whether that resolves in your favour over your remaining horizon is a question only you can answer.

But you should answer it with the full data in front of you.

The Fee Reality

Let’s talk about the number that never makes it into the pitch deck.

The PMS Value Framework

Gross Alpha > Fee = Value Added Gross Alpha ≈ Fee = Break-Even Gross Alpha < Fee = Value Destroyed

Applied to the 5-year window: net alpha is -3.40% per annum. That is already after the 2.5% fee has left your account.

Which means the gross return before fees was approximately 11.38% CAGR — still below the benchmark’s 12.28%.

The fee did not consume positive alpha here. The strategy delivered below-benchmark gross returns, and then charged you 2.5% on top.

Over 5 years, this places the NTDOP in the value-destroyed zone for investors in that cohort.

The since-inception picture is different. Gross return before fees: approximately 16.47% vs benchmark 11.46% — a gross alpha of 5.01%, of which 2.5% was consumed by the fee annually.

Net alpha: 2.51%. That is genuinely in the value-added zone.

But here is the uncomfortable truth: the since-inception alpha was largely built in the pre-2020 period, when the mid and small-cap opportunity was structurally underexploited. The last 5 years tell a different story.

Fee Drag on ₹50 Lakhs: The Rupee Picture

Scenario	Fee	Net Return	Corpus After 5 Years	Corpus After 7 Years
NTDOP (5Y CAGR)	2.5% p.a.	8.88%	₹75.4 lakhs	₹97.4 lakhs
Active Flexi-Cap MF (category median ~15%)	0.7–0.9% p.a.	~15%	₹1.00 crore	₹1.38 crore
Passive Index Fund (BSE 500 TRI, 0.15% fee)	0.15% p.a.	12.28%	₹88.8 lakhs	₹1.23 crore

Calculations use CAGR compounding on ₹50 lakhs initial corpus.

Sit with those numbers for a moment. On a ₹50 lakh investment over 5 years at the strategy’s net CAGR, you are at ₹75.4 lakhs.

The passive index fund — which you could have bought for 0.15% and forgotten about — would have given you ₹88.8 lakhs.

That is ₹13.4 lakhs more, in your account, without a fund manager, without a 2.5% fee, without a 31-stock concentrated portfolio carrying 16.7% standard deviation.

Over 7 years, that gap compounds to approximately ₹25.6 lakhs.

And the top-performing active flexi-cap mutual funds?

They delivered a category median of around 15% over the same period — giving you ₹1 crore on ₹50 lakhs, at under 1% expense ratio.

The mutual fund was cheaper, more liquid, tax-deferred on internal rebalancing, and delivered more.

That is the opportunity cost conversation you deserve to have.

The Zero-Based Thinking Test

This is the most important section in this article. Read it carefully.

Imagine you sold the NTDOP today. The money is in your bank account.

No prior history. No memory of the 2021 returns or the 2009 recovery.

No emotional attachment to the “next trillion dollar” thesis.

No sunk cost. You are simply an informed investor with ₹50 lakhs, reviewing your options from a clean slate.

Would you invest this money in the Motilal Oswal NTDOP today?

Before you answer, here is what you would be buying:

• A strategy that has delivered 8.88% CAGR net of fees over 5 years — in a market where the benchmark delivered 12.28% and good active flexi-cap funds delivered around 15%
• A portfolio carrying standard deviation of 16.7% vs the benchmark’s 13% — more volatility than the index, for less return
• A Sharpe ratio of 0.5 vs the benchmark’s 0.7 — meaning for every unit of risk you are taking; you are earning less than what the passive index generates per unit of its own risk
• A 2.5% annual fee that compounds against you in every year where gross alpha is negative or below the fee threshold
• A 2% exit load if you are still in Year 1 — one of the higher exit costs in the PMS category

Now ask yourself honestly: if someone presented you with these numbers today — fresh, no history — would you sign? Would you write the ₹50 lakh cheque?

If the answer is no, then what you are really doing by staying is letting inertia make a financial decision on your behalf.

And inertia does not have your interests at heart.

The exit is not a confession of failure.

The person who invested in this strategy 5 or 7 years ago made a considered decision based on a genuine 15-year track record and a compelling GDP growth thesis.

That was reasonable. What is not reasonable is allowing that same decision — made with different data, in a different market environment — to run forward on autopilot because reviewing it feels uncomfortable.

Staying invested is a choice. It requires a positive case — not just the absence of a reason to leave.

Can you articulate that case today, with the current numbers in front of you? If yes, stay with conviction.

If you are searching for the answer, that search is itself the answer.

Decision Factor Scorecard

Decision Factor	Rating	Analysis
Uniqueness vs Existing MF Portfolio	🟢 Pass	This is where the NTDOP earns genuine credit. At approximately 93% away from the BSE 500, the portfolio is not recycling the standard benchmark universe. The mid and small-cap tilt (48.9% and 26.3% respectively) means that if your mutual fund portfolio is anchored in large caps or index funds, this strategy is accessing a genuinely different opportunity set. Top holdings — Piramal Finance, IDFC First Bank, PG Electroplast, Ujjivan Small Finance Bank, Coforge — are names that don’t dominate typical large-cap MF portfolios. The differentiation argument holds here, unlike many all-cap PMS strategies that quietly park 60%+ in large caps. However, if your mutual fund portfolio already includes mid-cap or small-cap funds, you should check the overlap carefully before assuming this is additive.
Alpha Consistency Across All Periods	🟡 Mixed	The picture here is genuinely mixed, and that nuance matters. Over 1M, 3M, and 6M, the strategy is outperforming — which is encouraging in the current downturn environment. The 3-year alpha of essentially zero (+0.01%) suggests the strategy has broadly kept pace with the benchmark over that window. But the 5-year alpha of -3.40% per annum is a structural concern — that is not noise, it is a pattern. The since-inception alpha of +2.51% is real but increasingly carried by pre-2020 returns. Alpha consistency, scored honestly, is a mixed verdict: present in short windows and the long term, absent in the 1-year and 5-year windows that matter most to investors reviewing their position today.
Justification for PMS Premium Fee	🔴 Concern	The 5-year gross return before the 2.5% fee was approximately 11.38% CAGR — below the benchmark’s 12.28%. The fee, in this period, did not consume alpha. It compounded on top of a below-benchmark gross return. That places the 5-year experience in the value-destroyed zone. The since-inception case is stronger — gross alpha of approximately 5% before fees, net alpha of 2.51% after. But for an investor who entered in the last 3–5 years, the since-inception argument is someone else’s returns, not theirs. The relevant question is: for my cohort, for my entry point, has the 2.5% annual fee generated net value? For most investors in the last 5-year window, the honest answer is no.
Downside Protection in Market Corrections	🟡 Mixed	The short-term data here is actually positive. In the recent 6-month downturn, the NTDOP fell 3.97% against the benchmark’s 5.39% — a positive protection differential of 1.42%. In the 3-month window, the strategy rose 2.03% against the benchmark’s fall of 2.34% — a meaningful swing. This is what active management should deliver in adverse conditions. However, the standard deviation of 16.7% vs 13% over the 3-year period tells a different story — the strategy is structurally more volatile than the benchmark over longer horizons. In 2025, the strategy fell 5.82% and in 2026 YTD is down 7.02%. The downside protection verdict depends on your time horizon. Short-term: encouraging. Multi-year: the volatility profile is not consistent with a portfolio that is meaningfully protecting capital.
Portfolio Complement for MF Investor	🟢 Pass	Unlike many PMS strategies that masquerade as differentiated but hold the same Nifty 50 names in a slightly different proportion, the NTDOP genuinely accesses different territory. If your mutual fund portfolio is built around diversified large-cap or multi-cap funds, the NTDOP’s mid and small-cap tilt — with names like PG Electroplast, Ujjivan Small Finance Bank, Gravita India, Suzlon Energy, and Inox Wind — does represent genuine exposure that most mainstream mutual fund portfolios do not hold at meaningful weights. The complement test passes for large-cap-anchored MF investors. It does not pass for investors who already hold dedicated mid-cap and small-cap mutual funds — in that case, the overlap is real and the complement argument collapses.
Mandate Purity and Discipline	🟢 Pass	The evidence of mandate discipline is strong. Page Industries has been held since inception — 2007. Eight stocks have been held for over 12 years. The stated “Buy Right & Sit Tight” philosophy is not just a marketing tagline; the portfolio data supports it. Recent portfolio actions — exiting KPR Mill for better opportunity, entering IPCA Laboratories and NTPC with detailed published rationale — show an active, thinking manager rather than one running a closet index fund. The mandate is being executed with genuine conviction. That conviction has not always been rewarded by the market in the recent period, but the discipline itself is not in question.
Fund Manager Transparency	🟢 Pass	Monthly factsheets with stock-level attribution — top 5 contributors and bottom 5 detractors — are published consistently. Entry and exit rationales are detailed and public, covering the investment thesis, earnings data, and forward logic. The February 2026 one-pager includes the specific reasoning for adding IPCA Laboratories (domestic formulations growth, API export improvement, backward integration) and NTPC (capacity additions, fuel security, nuclear optionality). This level of communication is meaningfully above the category average. You know why the fund manager owns what they own. That transparency deserves credit.
Investment Horizon Suitability	🟡 Mixed	The strategy states a 3-year+ investment horizon. Over 3 years, the strategy has delivered approximately benchmark-level returns (13.46% vs 13.45%). Over 5 years, it has underperformed. Over the full 18-year horizon, it has outperformed meaningfully. The honest read: this is a strategy that requires genuine patience across full market cycles — the type of patience measured in decades, not years. The 2009 recovery (111%) and 2021 mid-cap rally (71.81%) are the moments that define the since-inception record. For an investor with a 10+ year horizon and strong emotional discipline, the thesis may still hold. For an investor with a 3–5 year review window, the 5-year data does not make a compelling case at 2.5% per year.
Market Cap Flexibility Utilisation	🟢 Pass	With only 20.9% in large caps and the remaining 75% in mid, small, and cash, the NTDOP is actually using its mandate’s flexibility. This is not a large-cap fund in disguise — it is a genuinely mid and small-cap oriented portfolio dressed in a multi-cap mandate. The Financial Services concentration (40.1%) is a deliberate sector bet, not an index-hugging move. Capital Goods at 16.9% and Healthcare at 7.1% round out a portfolio that looks nothing like the BSE 500. The market cap flexibility is being used actively and with conviction. Whether that conviction translates to alpha in the next 5 years is a separate question — but the flexibility is being utilised.
Concentration vs Diversification Balance	🟡 Mixed	31 stocks are moderately concentrated. The top 5 holdings account for roughly 25% of the portfolio, and the top 5 sectors account for 71.74%. Financial Services at 40.1% is a very heavy sector bet — in a strategy that is supposed to be capturing broad GDP themes, having nearly half the portfolio in one sector is a concentration risk that warrants attention. If private bank credit growth disappoints or NBFC stress emerges, the impact on this portfolio would be disproportionate. The concentration in Financial Services is a known, deliberate call — but it is also the single largest risk factor in the current portfolio that investors may not have fully priced into their expectations.
AUM Size and Strategy Capacity	🟡 Mixed	At ₹4,421 crores, the AUM is meaningful but not alarmingly large for a multi-cap mandate. However, with 75% of the portfolio in mid and small caps, there are real liquidity considerations when building or unwinding positions. A ₹3,316 crore mid and small-cap sleeve across 31 stocks means individual position sizes can approach ₹100–150 crore — a level at which price impact is a real constraint in less liquid names. AUM has grown significantly since the strategy’s early years, and that growth itself changes the opportunity set available to the fund manager. Smaller, higher-conviction positions in illiquid mid-caps become harder to execute cleanly at scale.
Manager Tenure and Continuity Risk	🟢 Pass	Mr. Vaibhav Agrawal is the CIO — Alternates at Motilal Oswal Asset Management, managing approximately ₹10,000 crore across alternate products. His tenure on this specific strategy and the continuity of the “Buy Right & Sit Tight” philosophy within the organisation provide meaningful stability. The philosophy itself is institutionalised — it predates the current manager’s formal CIO designation and is embedded in the firm’s equity culture. Key-person risk exists in any concentrated, high-conviction mandate, but the institutional depth at Motilal Oswal AMC partially mitigates it.

The Core Portfolio Architecture Question

If you have never thought about your portfolio this way, now is a good time to start.

Your core portfolio — the foundation of your long-term wealth — should work hardest at the lowest possible cost.

Diversified, liquid, low-fee instruments: index funds, flexi-cap funds, multi-asset allocations.

They give you broad market participation without the overhead of active management fees in years where active management doesn’t deliver.

Your satellite portfolio is where you take deliberate, differentiated bets.

Strategies that access what your core portfolio structurally cannot.

That genuinely add a new return stream. That go where mutual funds cannot follow.

Here is the important question for your specific situation: does the NTDOP still qualify as a genuine satellite?

If your core is large-cap and index-oriented — yes, the NTDOP’s mid and small-cap exposure is additive.

If your core already includes mid-cap and small-cap mutual funds — the overlap is real, and the satellite rationale weakens.

The NTDOP is one of the few PMS strategies in India where the differentiation argument is structurally credible.

The question is not whether it is differentiated — it is.

The question is whether the fee, the volatility, and the 5-year underperformance are proportionate to that differentiation in your specific portfolio context.

What a Genuinely Complementary PMS Looks Like

Think about whether your current allocation passes these tests.

A satellite PMS earns its place when it does things your mutual funds structurally cannot:

• Genuine mid and small-cap concentration in less-researched, under-owned businesses — not a 60%+ large-cap book dressed in a multi-cap label
• Gross alpha consistently above 4–6% per annum across multiple cycles, wide enough that the 2.5% fee still leaves meaningful net alpha in your account
• A mandate that is being actively and skilfully executed — not drifting toward the benchmark over time as AUM grows
• A Sharpe ratio that reflects better risk-adjusted returns than what the passive index delivers — not worse
• A portfolio that your existing mutual funds genuinely cannot replicate at scale

The NTDOP passes several of these tests in design.

The execution over the last 5 years raises the fee justification question squarely. That is the tension you are navigating.

Exit Considerations

If you have been sitting with these numbers and are thinking through your options, here is what you need to know before making any move.

Exit Load: 2% applies only in Year 1. After 12 months from your investment date, there is zero exit load. This is one of the cleaner exit structures in the PMS category — no multi-year lock-in. If you are past Year 1, the cost of exiting is purely a tax question.

Tax Treatment: Your NTDOP holdings sit directly in your Demat account. Every stock sale — whether on rebalancing by the fund manager or on your exit — triggers capital gains tax at the individual stock level. Positions held beyond 12 months: LTCG at 12.5%. Positions held under 12 months: STCG at 20%. This is structurally different from mutual funds, where tax is deferred until you personally redeem. Ask your relationship manager for a position-level holding period statement before deciding to exit — the tax liability can vary significantly.

Staggered Exit: If your unrealised gains are large and the tax liability concentrated, consider spreading the redemption across two financial years to manage LTCG thresholds and avoid a single, compressive tax event.

Timing: The NTDOP is currently down 3.97% over 6 months, with CY 2026 YTD at -7.02%. Exiting at depressed prices in your mid and small-cap positions may crystallise losses that could recover. If you have a 2+ year horizon and no liquidity need, there is no urgency. But the portfolio fit question is structural — and it can be answered independently of where the market is today.

Key Takeaways

If you take nothing else from this review, take these eight points and sit with them.

1. The NTDOP’s since-inception CAGR of 13.97% is genuine — 18 years of data is not marketing fiction. But the 5-year CAGR of 8.88% vs the benchmark’s 12.28% is the number that matters most for anyone reviewing their position today.
2. The strategy is structurally differentiated — 93% away from BSE 500, genuinely mid and small-cap oriented. This is one of the few PMS strategies where the uniqueness argument holds.
3. The 5-year gross return before the fee was approximately 11.38% — already below the benchmark before the 2.5% fee was applied. The fee is not consuming alpha; it is compounding on a below-index base.
4. The risk-adjusted picture is uncomfortable: standard deviation of 16.7% vs 13%, Sharpe ratio of 0.5 vs 0.7. You are taking more active risk than the benchmark and receiving less return per unit of that risk.
5. The 2-year CAGR is exactly 4.14% vs 4.14% — two years of concentrated, active management, 2.5% fee paid, and the benchmark matched you precisely.
6. Exit load after Year 1 is zero — if you are reviewing portfolio fit, the mechanical cost of moving is lower than it may feel.
7. The complement argument is strongest for investors with large-cap and index-heavy core portfolios. If you already own mid-cap or small-cap mutual funds, verify the overlap before assuming this is additive.
8. Staying invested is a choice. It requires a positive thesis — not just inertia. Can you state yours clearly, with the current data in front of you?

FAQ

These are the questions we hear most often from investors holding this strategy.

1. Is Motilal Oswal NTDOP a good investment?

It has a credible 18-year track record with genuine outperformance since inception. However, the 5-year net CAGR of 8.88% trails the benchmark by 3.40% per annum, and the risk-adjusted metrics (Sharpe 0.5 vs 0.7) raise real questions for investors reviewing their position today.

2. How has the NTDOP performed vs its benchmark?

As of May 2026, the strategy outperforms over the short term (1M, 3M, 6M) and since inception (+2.51% alpha). Over 5 years, it underperforms by 3.40% per annum. Over 2 and 3 years, it matches the benchmark. The picture is genuinely mixed across periods.

3. What is the NTDOP fee structure?

The fixed fee option is 2.5% per annum. The variable option has a 20% profit sharing above an 8% hurdle. The exit load is 2% in Year 1, Nil thereafter.

4. What is the minimum investment for Motilal Oswal NTDOP?

₹50 lakhs.

5. Is the NTDOP fee justified?

Over the since-inception period, the net alpha of 2.51% suggests the fee has been broadly earned. Over the last 5 years, gross return before the fee was below the benchmark — meaning the fee was charged on a below-index gross return. For investors in the 5-year cohort, the fee justification is not strong.

6. Does the NTDOP overlap with my mutual fund portfolio?

Less than most PMS strategies. At ~93% away from BSE 500 and with 75% in mid and small caps, the overlap with standard large-cap or flexi-cap mutual funds is limited. However, if your portfolio includes dedicated mid-cap or small-cap mutual funds, you should do a stock-level overlap check.

7. What is the exit load on Motilal Oswal NTDOP?

The exit load of Motilal Oswal NTDOP is 2% if you exit within Year 1 of each investment tranche. Zero exit load after 12 months.

8. Why has the NTDOP underperformed over 5 years?

The strategy’s heavy concentration in Financial Services (40.1%) and Capital Goods, with limited exposure to the PSU, commodity, and energy sectors that drove benchmark returns from 2021–2024, created a structural style headwind. The mid and small-cap tilt also experienced a meaningful correction in 2024–2025.

9. How does the NTDOP compare to a mutual fund?

On a 5-year basis, the NTDOP delivered 8.88% net vs a passive index at ~12.13% and category-median active flexi-cap funds at ~15%. The NTDOP charged 2.5% vs under 1% for mutual funds. Mutual funds also defer tax on internal rebalancing, creating a structural compounding advantage.

10. Should I exit the Motilal Oswal NTDOP?

That depends on your entry date, existing portfolio composition, remaining investment horizon, and tax position. A professional portfolio review — mapping your actual holdings and returns against current alternatives — is the right first step. We offer that at no cost to HNI investors.

Our Approach

At Holistic Financial Services, we study PMS strategies across the market — not to replace your mutual fund portfolio, but to identify the rare few that genuinely complement it.

A PMS earns its place only when it adds a return stream your existing funds cannot access, without duplicating what you already own.

If you’d like to sit down and map your NTDOP against your existing holdings, we offer a complimentary portfolio review for HNI investors.

Bring your statement.

We’ll tell you honestly whether this strategy is complementing your portfolio or quietly competing with it.